학술논문
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Document Type
Article
Author
Ferrante, Marc ; Panaccione, Remo; Baert, Filip; Bossuyt, Peter; Colombel, Jean-Frederic; Danese, Silvio; Dubinsky, Marla; Feagan, Brian G; Hisamatsu, Tadakazu; Lim, Allen; Lindsay, James O; Loftus, Edward V, Jr; Panés, Julián; Peyrin-Biroulet, Laurent; Ran, Zhihua; Rubin, David T; Sandborn, William J; Schreiber, Stefan; Neimark, Ezequiel; Song, Alexandra; Kligys, Kristina; Pang, Yinuo; Pivorunas, Valerie; Berg, Sofie; Duan, W Rachel; Huang, Bidan; Kalabic, Jasmina; Liao, Xiaomei; Robinson, Anne; Wallace, Kori; D'Haens, Geert
Source
In The Lancet 28 May-3 June 2022 399(10340):2031-2046
Subject
Language
ISSN
0140-6736